Company Information

  

Address: 1616 EASTLAKE AVENUE E.
SUITE 310 
City: SEATTLE 
State: WA 
Zip Code: 98102 
Telephone: (650) 392-8350 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a late-stage immunotherapy company employing next-generation, diversified in vivo approaches designed to enable the body's immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have designed our technologies to activate the immune system's natural ability to generate and/or expand tumor-specific cytotoxic T cells, or CTLs, while also enhancing other immune effectors, to fight cancer via distinct mechanisms. CMB305 and G100, our lead product candidates, use the body's immune system in different ways that, we believe, address the shortcomings of other therapies and have the potential to treat a broad patient population either as monotherapies or in combination with other mechanisms of action. In 2017, we presented positive single-arm and randomized data for CMB305 and G100 in soft tissue sarcoma and follicular NHL patients, respectively, and after meeting with the U.S.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.53NAN/E
12/2017-1.75NAN/E
09/2017-2.11NAN/E
06/2017-2.19NAN/E
03/2017-2.36NAN/E
12/2016-2.47NAN/E
09/2016-2.53NAN/E
06/2016-2.28NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.14Total Liab/Total Assets0.10
Net Inc/Total Assets-0.34Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.37Total Liab/Comm Equity0.04
Pretax Inc/Net Sales-7.21Interest Coverage RatioNA
Net Inc/Net Sales-7.21Curr Debt/EquityNA
Cash Flow/Net Sales-7.37LTD/EquityNA
SG&A/NetSales2.26Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover1.93Quick Ratio10.50
Inventory Turnover0.13Current Ratio10.55
Inventory Day Sales0.00Net Rec/Curr Assets0.02
Net Sales/Work Cap0.05Inv/Curr Assets0.00
Net Sales/PP&E14.65  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.50 0.49 0.52 0.73
Cost of Goods Sold 0.01 0.01 0.02 0.02
Selling & Admin Exps 4.00 4.32 3.91 3.89
Operating Income -13.81 -12.37 -13.66 -14.04
Interest Exp NA NA NA NA
Pretax Income -13.30 -11.98 -13.42 -13.85
Other Income 0.51 0.39 0.24 0.19
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -13.30 -11.98 -13.42 -13.85

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 130.88 147.11 70.34 87.28
Receivables - Total 0.44 3.78 3.63 0.62
Inventories - Total 0.67 0.68 0.61 0.62
Total Current Assets 134.50 153.14 77.02 89.84
Net Property, Plant & Equipment 0.61 0.49 0.50 0.51
Total Assets 135.31 153.83 78.07 90.87
Liabilities        
Accounts Payable 6.35 8.52 8.13 9.97
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 6.35 14.52 15.39 17.25
Long-Term Debt NA NA NA NA
Total Liabilities 6.46 14.62 15.48 17.33
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.05 0.03 0.03
Retained Earnings -249.06 -235.76 -223.78 -210.36
Treasury Stock NA NA NA NA
Total Stockholders' Equity 128.86 139.21 62.59 73.54
Total Liabilities and Stockholders' Equity 135.31 153.83 78.07 90.87

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -16.38 -9.84 -17.18 -14.86
Net Cash Provided by Investing Activities 9.88 -32.73 9.95 15.94
Net Cash Provided by Financing Activities 0.23 86.66 0.29 0.11

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20131.60-15.98--
12/20146.43-34.15-4.56
12/20159.51-39.44-2.06
12/201613.26-53.53-2.47
12/20177.20-51.86-1.75
Growth Rates45.65----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/188924,42150.75




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.